Thymosin Alpha-1
Also searched as: Ta1 · Zadaxin · thymalfasin
Thymosin Alpha-1 is a peptide first isolated from thymic tissue, studied for its role in immune signalling. It is approved as a medicine in a number of countries, though not in the UK or the United States, and is marketed under the name Zadaxin where licensed.
What the research has looked at
- Chronic hepatitis B and C, in trials in licensing countries
- Immune response in sepsis, in randomised trials
- Vaccine response in older adults
- T-cell maturation and signalling in laboratory studies
This is a description of what has been studied, not a claim about what it does. Evidence level: human trials.
Legal position in the UK
Not a licensed medicine in the UKNo UK marketing authorisation. Licensed as a medicine in a number of other countries for specific indications. Prohibited in sport under WADA class S2.
Handling and storage
Where licensed, supplied as a lyophilised powder with manufacturer reconstitution instructions, which take precedence.
Vial sizes: Commonly 1.6mg or 5mg per vial. Where a manufacturer supplies handling instructions, those take precedence over anything general.
Questions
- Is Thymosin Alpha-1 approved?
- In roughly 35 countries, for indications including chronic hepatitis. Not in the UK and not in the United States.
- Is it the same as TB-500?
- No. Different molecule, different family, different research area. Thymosin Alpha-1 is a 28-amino-acid immune-signalling peptide; TB-500 is a seven-amino-acid fragment of Thymosin Beta-4.